Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection - Jacobson, Ira M; McHutchison, John G; Dusheiko, Geoffrey; Di Bisceglie, Adrian M; Reddy, K. Rajender; Bzowej, Natalie H; Marcellin, Patrick; Muir, Andrew J; Ferenci, Peter; Flisiak, Robert; George, Jacob; George, Shelley; et al. (The New England journal of medicine, 2011)
Keywords: Adult; Aged; Antibiotics. Antiinfectious agents. Antiparasitic agents; Antiretroviral drugs; Antiviral agents; Antiviral Agents - adverse effects; Antiviral Agents - therapeutic use; Antiviral drugs; Biological and medical sciences; Chronic infection; Clinical trials; Double-Blind Method; Drug Therapy, Combination; Employees; Fees & charges; Female; General aspects; Genomes; Genotype & phenotype; Genotypes; Hepacivirus - genetics; Hepacivirus - isolation & purification; Hepatitis; Hepatitis C; Hepatitis C, Chronic - drug therapy; Hepatitis C, Chronic - virology; Human viral diseases; Humans; Infections; Infectious diseases; Interferon; Interferon-alpha - adverse effects; Interferon-alpha - therapeutic use; Liver cancer; Liver diseases; Logistic Models; Male; Medical sciences; Middle Aged; Oligopeptides - adverse effects; Oligopeptides - therapeutic use; Patients; Pharmaceuticals; Pharmacology. Drug treatments; Polyethylene Glycols - adverse effects; Polyethylene Glycols - therapeutic use; Proteinase inhibitors; Recombinant Proteins; Ribavirin; Ribonucleic acid; RNA; RNA, Viral - blood; Sequence Analysis, DNA; Serine Proteinase Inhibitors - adverse effects; Serine Proteinase Inhibitors - therapeutic use; Skin; Viral diseases; Viral hepatitis; Viral Load; Young Adult; Infection; Medicine; Viral disease; Digestive diseases; Hepatic disease; Antiviral; Telaprevir; Protease inhibitor; Viral hepatitis C